Adverse Drug Reaction Overview
The safety of IBRANCE has been assessed in 2 randomized studies of patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The most common adverse drug reactions of any grade reported in ≥10% of patients receiving palbociclib in combination with endocrine treatment were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, thrombocytopenia, diarrhea, alopecia, vomiting, decreased appetite, and rash.
Most patients treated with IBRANCE (palbociclib) experienced myelosuppressive effects with over half experiencing Grade 3 neutropenia at some point during treatment. Thrombocytopenia and anemia were less commonly observed. Myelosuppressive effects can be expected to occur from Cycle 1 forward.
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
The adverse reactions are listed by system organ class, frequency category and grade of severity.
Frequency categories are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
The safety of IBRANCE (125 mg/day) plus letrozole (2.5 mg/day) versus placebo plus letrozole was evaluated in PALOMA-2 The data described below reflect exposure to IBRANCE in 444 out of 666 patients with ER‑positive, HER2‑negative advanced breast cancer who received at least 1 dose of IBRANCE plus letrozole in PALOMA-2. Patients were randomized 2:1 to receive the combination IBRANCE plus letrozole versus placebo plus letrozole. The median duration of treatment for IBRANCE plus letrozole was 19.8 months while the median duration of treatment for placebo plus letrozole arm was 13.8 months.
Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus letrozole. No dose reduction was allowed for letrozole in PALOMA-2.
Permanent treatment discontinuation associated with an adverse reaction occurred in 43 of 444 (10%) patients receiving IBRANCE plus letrozole and in 13 of 222 (6%) patients receiving placebo plus letrozole. Adverse reactions leading to permanent discontinuation for patients receiving IBRANCE plus letrozole included neutropenia (1%) and alanine aminotransferase increase (0.7%).
The most common adverse reactions (≥10%) of any grade reported in patients in the IBRANCE plus letrozole arm by descending frequency were neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, and dysgeusia.
The most frequently reported serious adverse reactions (≥1%) in patients receiving IBRANCE plus letrozole were Infections (20%) and Febrile neutropenia (2%).
Adverse reactions (≥5%) reported in patients who received IBRANCE plus letrozole or placebo plus letrozole in PALOMA-2 are listed in Table 1.
IBRANCE plus Letrozole (N=444) | Placebo plus Letrozole (N=222) | |||||
---|---|---|---|---|---|---|
Adverse Reaction | All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % |
Blood and lymphatic system disorders | ||||||
Neutropeniaa | 80 | 56 | 10 | 6 | 1 | 1 |
Leukopeniab | 39 | 24 | 1 | 2 | 0 | 0 |
Anemiac | 24 | 5 | <1 | 9 | 2 | 0 |
Thrombocytopeniad | 16 | 1 | <1 | 1 | 0 | 0 |
Eye Disorders | ||||||
lacrimation increased | 6 | 0 | 0 | 1 | 0 | 0 |
Gastrointestinal disorders | ||||||
Stomatitise | 30 | 1 | 0 | 14 | 0 | 0 |
Nausea | 35 | <1 | 0 | 26 | 2 | 0 |
Diarrhea | 26 | 1 | 0 | 19 | 1 | 0 |
Vomiting | 16 | 1 | 0 | 17 | 1 | 0 |
General disorders and administration site conditions | ||||||
Fatigue | 37 | 2 | 0 | 28 | 1 | 0 |
Asthenia | 17 | 2 | 0 | 12 | 0 | 0 |
Pyrexia | 12 | 0 | 0 | 9 | 0 | 0 |
Infections and infestations | ||||||
Infectionsf, g | 60 | 6 | 1 | 42 | 3 | 0 |
Investigations | ||||||
Alanine aminotransferase increased | 10 | 2 | <1 | 4 | 0 | 0 |
Aspartate aminotransferase increased | 10 | 3 | 0 | 5 | 1 | 0 |
Metabolism and nutrition disorders | ||||||
Decreased appetite | 15 | 1 | 0 | 9 | 0 | 0 |
Nervous system disorders | ||||||
Dysgeusia | 10 | 0 | 0 | 5 | 0 | 0 |
Respiratory, thoracic and mediastinal disorders | ||||||
Epistaxis | 9 | 0 | 0 | 6 | 0 | 0 |
Skin and subcutaneous tissue disorders | ||||||
Alopecia | 33 | N/A | N/A | 16 | N/A | N/A |
Rashh | 18 | 1 | 0 | 12 | 1 | 0 |
Dry skin | 12 | 0 | 0 | 6 | 0 | 0 |
Grading according to CTCAE 4.0.
|
Additional adverse reactions occurring at an overall incidence of <5% of patients receiving IBRANCE plus letrozole in PALOMA-2 included dry eye (4.1%), vision blurred (3.6%), and febrile neutropenia (2.5%).
IBRANCE plus Letrozole (N=444) | Placebo plus Letrozole (N=222) | |||||
---|---|---|---|---|---|---|
Laboratory Test Abnormality | All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % |
WBC decreased | 97 | 35 | 1 | 25 | 1 | 0 |
Neutrophils decreased | 95 | 56 | 12 | 20 | 1 | 1 |
Anemia | 78 | 6 | 0 | 42 | 2 | 0 |
Platelets decreased | 63 | 1 | 1 | 14 | 0 | 0 |
Aspartate aminotransferase increased | 52 | 3 | 0 | 34 | 1 | 0 |
Alanine aminotransferase increased | 43 | 2 | <1 | 30 | 0 | 0 |
N=number of patients; WBC=white blood cells. |
The safety of IBRANCE (125 mg/day) plus fulvestrant (500 mg) versus placebo plus fulvestrant was evaluated in a randomized, controlled, Phase 3 trial (PALOMA-3). The data described below reflect exposure to IBRANCE in 345 out of 517 patients with HR-positive, HER2-negative metastatic breast cancer who received at least 1 dose of IBRANCE in PALOMA-3. Patients were randomized 2:1 to receive the combination IBRANCE plus fulvestrant versus placebo plus fulvestrant.
The most common adverse reactions (≥10%) of any grade reported in patients in the IBRANCE plus fulvestrant arm were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, headache, diarrhea, thrombocytopenia, constipation, vomiting, alopecia, rash, decreased appetite, and pyrexia.
The most frequently reported serious adverse reactions in patients receiving IBRANCE plus fulvestrant were infections (3%), pyrexia (1%), neutropenia (1%), and pulmonary embolism (1%).
Adverse reactions reported in patients who received IBRANCE plus fulvestrant or placebo plus fulvestrant in PALOMA-3 are listed in Table 3.
Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus fulvestrant. No dose reduction was allowed for fulvestrant in PALOMA-3.
Permanent discontinuation associated with an adverse reaction occurred in 19 of 345 (6%) patients receiving IBRANCE plus fulvestrant, and in 6 of 172 (3%) patients receiving placebo plus fulvestrant. Adverse reactions leading to permanent discontinuation for those patients receiving IBRANCE plus fulvestrant included fatigue (0.6%), infections (0.6%), and thrombocytopenia (0.6%).
Treatment-emergent adverse events presented in Table 3 below are based on a median duration of treatment of approximately 5 months for patients on the IBRANCE plus fulvestrant arm, and approximately 4 months for patients on the placebo plus fulvestrant arm.
Adverse Reaction | IBRANCE plus Fulvestrant (N=345) | Placebo plus Fulvestrant (N=172) | ||||
---|---|---|---|---|---|---|
All Grades | Grade 3 | Grade 4 | All Grades | Grade 3 | Grade 4 | |
% | % | % | % | % | % | |
Blood and lymphatic system disorders | ||||||
Neutropeniaa | 79 | 53 | 9 | 4 | 0 | <1 |
Leukopeniab | 46 | 25 | <1 | 4 | 0 | 1 |
Anemiac | 26 | 3 | 0 | 10 | 2 | 0 |
Thrombocytopeniad | 19 | 2 | <1 | 0 | 0 | 0 |
Gastrointestinal disorders | ||||||
Nausea | 29 | 0 | 0 | 26 | <1 | 0 |
Stomatitise | 25 | <1 | 0 | 11 | 0 | 0 |
Diarrhea | 19 | 0 | 0 | 17 | <1 | 0 |
Constipation | 17 | 0 | 0 | 14 | 0 | 0 |
Vomiting | 15 | <1 | 0 | 12 | <1 | 0 |
Abdominal Pain | 6 | <1 | 0 | 5 | 0 | 0 |
General disorders and administration site conditions | ||||||
Fatigue | 38 | 2 | 0 | 27 | 1 | 0 |
Asthenia | 7 | 0 | 0 | 5 | 1 | 0 |
Pyrexia | 9 | <1 | 0 | 4 | 0 | 0 |
Oedema peripheral | 8 | 0 | 0 | 5 | 0 | 0 |
Infections and infestations | ||||||
Infectionsf | 34 | 1 | <1 | 24 | 2 | 0 |
Metabolism and nutrition disorders | ||||||
Decreased appetite | 13 | <1 | 0 | 8 | 0 | 0 |
Nervous system disorders | ||||||
Headache | 21 | <1 | 0 | 17 | 0 | 0 |
Dysgeusia | 6 | 0 | 0 | 2 | 0 | 0 |
Dizziness | 11 | <1 | 0 | 9 | 0 | 0 |
Psychiatric disorders | ||||||
Insomnia | 11 | <1 | 0 | 7 | 0 | 0 |
Respiratory, thoracic and mediastinal disorders | ||||||
Epistaxis | 6 | 0 | 0 | 1 | 0 | 0 |
Cough | 13 | 0 | 0 | 11 | 0 | 0 |
Dyspnoea | 7 | 0 | 0 | 4 | 0 | 0 |
Skin and subcutaneous tissue disorders | ||||||
Alopecia | 15 | N/A | N/A | 6 | N/A | N/A |
Rashg | 14 | <1 | 0 | 5 | 0 | 0 |
SOC Investigations | ||||||
Aspartate aminotransferase increased | 6 | 2 | 0 | 5 | 1 | 0 |
|
Additional adverse reactions occurring at an overall incidence of <5% of patients receiving IBRANCE plus fulvestrant in Study PALOMA-3 included dry skin (4.9%), Vision blurred (4.9%), alanine aminotransferase increased (4.6%), lacrimation increased (4.3%), dry eye (2.9%), and febrile neutropenia (0.6%).
IBRANCE + Fulvestrant (N=345) | Placebo Plus Fulvestrant (N=172) | |||||
---|---|---|---|---|---|---|
Laboratory Abnormality | All Grades | Grade 3 | Grade 4 | All Grades | Grade 3 | Grade 4 |
% | % | % | % | % | % | |
White blood cells decreased | 98 | 40 | 1 | 22 | 0 | <1 |
Neutrophils decreased | 95 | 53 | 9 | 11 | 0 | 1 |
Anemia | 76 | 3 | 0 | 36 | 2 | 0 |
Platelets decreased | 57 | 2 | 1 | 8 | 0 | 0 |
N=number of subjects. |
Updated safety data for patients on the IBRANCE plus fulvestrant arm, based on an approximate 6-month increase in the median duration of treatment, were generally consistent with the safety table provided in Tables 3 and 4. No new safety concerns have been identified.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of IBRANCE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Respiratory disorders: Interstitial lung disease (ILD)/non-infectious pneumonitis, including fatal cases.
)Adverse Drug Reaction Overview
The safety of IBRANCE has been assessed in 2 randomized studies of patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The most common adverse drug reactions of any grade reported in ≥10% of patients receiving palbociclib in combination with endocrine treatment were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, thrombocytopenia, diarrhea, alopecia, vomiting, decreased appetite, and rash.
Most patients treated with IBRANCE (palbociclib) experienced myelosuppressive effects with over half experiencing Grade 3 neutropenia at some point during treatment. Thrombocytopenia and anemia were less commonly observed. Myelosuppressive effects can be expected to occur from Cycle 1 forward.
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
The adverse reactions are listed by system organ class, frequency category and grade of severity.
Frequency categories are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
The safety of IBRANCE (125 mg/day) plus letrozole (2.5 mg/day) versus placebo plus letrozole was evaluated in PALOMA-2 The data described below reflect exposure to IBRANCE in 444 out of 666 patients with ER‑positive, HER2‑negative advanced breast cancer who received at least 1 dose of IBRANCE plus letrozole in PALOMA-2. Patients were randomized 2:1 to receive the combination IBRANCE plus letrozole versus placebo plus letrozole. The median duration of treatment for IBRANCE plus letrozole was 19.8 months while the median duration of treatment for placebo plus letrozole arm was 13.8 months.
Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus letrozole. No dose reduction was allowed for letrozole in PALOMA-2.
Permanent treatment discontinuation associated with an adverse reaction occurred in 43 of 444 (10%) patients receiving IBRANCE plus letrozole and in 13 of 222 (6%) patients receiving placebo plus letrozole. Adverse reactions leading to permanent discontinuation for patients receiving IBRANCE plus letrozole included neutropenia (1%) and alanine aminotransferase increase (0.7%).
The most common adverse reactions (≥10%) of any grade reported in patients in the IBRANCE plus letrozole arm by descending frequency were neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, and dysgeusia.
The most frequently reported serious adverse reactions (≥1%) in patients receiving IBRANCE plus letrozole were Infections (20%) and Febrile neutropenia (2%).
Adverse reactions (≥5%) reported in patients who received IBRANCE plus letrozole or placebo plus letrozole in PALOMA-2 are listed in Table 1.
IBRANCE plus Letrozole (N=444) | Placebo plus Letrozole (N=222) | |||||
---|---|---|---|---|---|---|
Adverse Reaction | All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % |
Blood and lymphatic system disorders | ||||||
Neutropeniaa | 80 | 56 | 10 | 6 | 1 | 1 |
Leukopeniab | 39 | 24 | 1 | 2 | 0 | 0 |
Anemiac | 24 | 5 | <1 | 9 | 2 | 0 |
Thrombocytopeniad | 16 | 1 | <1 | 1 | 0 | 0 |
Eye Disorders | ||||||
lacrimation increased | 6 | 0 | 0 | 1 | 0 | 0 |
Gastrointestinal disorders | ||||||
Stomatitise | 30 | 1 | 0 | 14 | 0 | 0 |
Nausea | 35 | <1 | 0 | 26 | 2 | 0 |
Diarrhea | 26 | 1 | 0 | 19 | 1 | 0 |
Vomiting | 16 | 1 | 0 | 17 | 1 | 0 |
General disorders and administration site conditions | ||||||
Fatigue | 37 | 2 | 0 | 28 | 1 | 0 |
Asthenia | 17 | 2 | 0 | 12 | 0 | 0 |
Pyrexia | 12 | 0 | 0 | 9 | 0 | 0 |
Infections and infestations | ||||||
Infectionsf, g | 60 | 6 | 1 | 42 | 3 | 0 |
Investigations | ||||||
Alanine aminotransferase increased | 10 | 2 | <1 | 4 | 0 | 0 |
Aspartate aminotransferase increased | 10 | 3 | 0 | 5 | 1 | 0 |
Metabolism and nutrition disorders | ||||||
Decreased appetite | 15 | 1 | 0 | 9 | 0 | 0 |
Nervous system disorders | ||||||
Dysgeusia | 10 | 0 | 0 | 5 | 0 | 0 |
Respiratory, thoracic and mediastinal disorders | ||||||
Epistaxis | 9 | 0 | 0 | 6 | 0 | 0 |
Skin and subcutaneous tissue disorders | ||||||
Alopecia | 33 | N/A | N/A | 16 | N/A | N/A |
Rashh | 18 | 1 | 0 | 12 | 1 | 0 |
Dry skin | 12 | 0 | 0 | 6 | 0 | 0 |
Grading according to CTCAE 4.0.
|
Additional adverse reactions occurring at an overall incidence of <5% of patients receiving IBRANCE plus letrozole in PALOMA-2 included dry eye (4.1%), vision blurred (3.6%), and febrile neutropenia (2.5%).
IBRANCE plus Letrozole (N=444) | Placebo plus Letrozole (N=222) | |||||
---|---|---|---|---|---|---|
Laboratory Test Abnormality | All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % |
WBC decreased | 97 | 35 | 1 | 25 | 1 | 0 |
Neutrophils decreased | 95 | 56 | 12 | 20 | 1 | 1 |
Anemia | 78 | 6 | 0 | 42 | 2 | 0 |
Platelets decreased | 63 | 1 | 1 | 14 | 0 | 0 |
Aspartate aminotransferase increased | 52 | 3 | 0 | 34 | 1 | 0 |
Alanine aminotransferase increased | 43 | 2 | <1 | 30 | 0 | 0 |
N=number of patients; WBC=white blood cells. |
The safety of IBRANCE (125 mg/day) plus fulvestrant (500 mg) versus placebo plus fulvestrant was evaluated in a randomized, controlled, Phase 3 trial (PALOMA-3). The data described below reflect exposure to IBRANCE in 345 out of 517 patients with HR-positive, HER2-negative metastatic breast cancer who received at least 1 dose of IBRANCE in PALOMA-3. Patients were randomized 2:1 to receive the combination IBRANCE plus fulvestrant versus placebo plus fulvestrant.
The most common adverse reactions (≥10%) of any grade reported in patients in the IBRANCE plus fulvestrant arm were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, headache, diarrhea, thrombocytopenia, constipation, vomiting, alopecia, rash, decreased appetite, and pyrexia.
The most frequently reported serious adverse reactions in patients receiving IBRANCE plus fulvestrant were infections (3%), pyrexia (1%), neutropenia (1%), and pulmonary embolism (1%).
Adverse reactions reported in patients who received IBRANCE plus fulvestrant or placebo plus fulvestrant in PALOMA-3 are listed in Table 3.
Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus fulvestrant. No dose reduction was allowed for fulvestrant in PALOMA-3.
Permanent discontinuation associated with an adverse reaction occurred in 19 of 345 (6%) patients receiving IBRANCE plus fulvestrant, and in 6 of 172 (3%) patients receiving placebo plus fulvestrant. Adverse reactions leading to permanent discontinuation for those patients receiving IBRANCE plus fulvestrant included fatigue (0.6%), infections (0.6%), and thrombocytopenia (0.6%).
Treatment-emergent adverse events presented in Table 3 below are based on a median duration of treatment of approximately 5 months for patients on the IBRANCE plus fulvestrant arm, and approximately 4 months for patients on the placebo plus fulvestrant arm.
Adverse Reaction | IBRANCE plus Fulvestrant (N=345) | Placebo plus Fulvestrant (N=172) | ||||
---|---|---|---|---|---|---|
All Grades | Grade 3 | Grade 4 | All Grades | Grade 3 | Grade 4 | |
% | % | % | % | % | % | |
Blood and lymphatic system disorders | ||||||
Neutropeniaa | 79 | 53 | 9 | 4 | 0 | <1 |
Leukopeniab | 46 | 25 | <1 | 4 | 0 | 1 |
Anemiac | 26 | 3 | 0 | 10 | 2 | 0 |
Thrombocytopeniad | 19 | 2 | <1 | 0 | 0 | 0 |
Gastrointestinal disorders | ||||||
Nausea | 29 | 0 | 0 | 26 | <1 | 0 |
Stomatitise | 25 | <1 | 0 | 11 | 0 | 0 |
Diarrhea | 19 | 0 | 0 | 17 | <1 | 0 |
Constipation | 17 | 0 | 0 | 14 | 0 | 0 |
Vomiting | 15 | <1 | 0 | 12 | <1 | 0 |
Abdominal Pain | 6 | <1 | 0 | 5 | 0 | 0 |
General disorders and administration site conditions | ||||||
Fatigue | 38 | 2 | 0 | 27 | 1 | 0 |
Asthenia | 7 | 0 | 0 | 5 | 1 | 0 |
Pyrexia | 9 | <1 | 0 | 4 | 0 | 0 |
Oedema peripheral | 8 | 0 | 0 | 5 | 0 | 0 |
Infections and infestations | ||||||
Infectionsf | 34 | 1 | <1 | 24 | 2 | 0 |
Metabolism and nutrition disorders | ||||||
Decreased appetite | 13 | <1 | 0 | 8 | 0 | 0 |
Nervous system disorders | ||||||
Headache | 21 | <1 | 0 | 17 | 0 | 0 |
Dysgeusia | 6 | 0 | 0 | 2 | 0 | 0 |
Dizziness | 11 | <1 | 0 | 9 | 0 | 0 |
Psychiatric disorders | ||||||
Insomnia | 11 | <1 | 0 | 7 | 0 | 0 |
Respiratory, thoracic and mediastinal disorders | ||||||
Epistaxis | 6 | 0 | 0 | 1 | 0 | 0 |
Cough | 13 | 0 | 0 | 11 | 0 | 0 |
Dyspnoea | 7 | 0 | 0 | 4 | 0 | 0 |
Skin and subcutaneous tissue disorders | ||||||
Alopecia | 15 | N/A | N/A | 6 | N/A | N/A |
Rashg | 14 | <1 | 0 | 5 | 0 | 0 |
SOC Investigations | ||||||
Aspartate aminotransferase increased | 6 | 2 | 0 | 5 | 1 | 0 |
|
Additional adverse reactions occurring at an overall incidence of <5% of patients receiving IBRANCE plus fulvestrant in Study PALOMA-3 included dry skin (4.9%), Vision blurred (4.9%), alanine aminotransferase increased (4.6%), lacrimation increased (4.3%), dry eye (2.9%), and febrile neutropenia (0.6%).
IBRANCE + Fulvestrant (N=345) | Placebo Plus Fulvestrant (N=172) | |||||
---|---|---|---|---|---|---|
Laboratory Abnormality | All Grades | Grade 3 | Grade 4 | All Grades | Grade 3 | Grade 4 |
% | % | % | % | % | % | |
White blood cells decreased | 98 | 40 | 1 | 22 | 0 | <1 |
Neutrophils decreased | 95 | 53 | 9 | 11 | 0 | 1 |
Anemia | 76 | 3 | 0 | 36 | 2 | 0 |
Platelets decreased | 57 | 2 | 1 | 8 | 0 | 0 |
N=number of subjects. |
Updated safety data for patients on the IBRANCE plus fulvestrant arm, based on an approximate 6-month increase in the median duration of treatment, were generally consistent with the safety table provided in Tables 3 and 4. No new safety concerns have been identified.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of IBRANCE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Respiratory disorders: Interstitial lung disease (ILD)/non-infectious pneumonitis, including fatal cases.
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.
To report an adverse event related to COMIRNATY, and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.